Roche says Kadcyla wins European approval [ BeritaTerkini ]

<div id="yom-ad-LREC" class="yom-ad yom-ad-LREC"> <center> <div id="yom-ad-LREC-iframe" class="yom-ad"></div> </center> </div> <p><br></p> <div class="body-slot-container"> <div class="body-slot-mod"> <div class="yom-remote"> <div class="yom-loading" id="mediacontentrelatedstory_container"></div> </div> </div> </div> <p>ZURICH (Reuters) – Roche said on Wednesday its drug Kadcyla, a treatment for an aggressive form of breast cancer, had been approved in Europe following U.S. approval in February.</p> <p>Kadcyla treats patients with late-stage disease whose cancer cells contain increased amounts of a protein known as HER2.</p> <p>It works by attaching Herceptin to a drug called DM1, developed by ImmunoGen, which interferes with cancer cell growth. ImmunoGen will receive a $ 5 million milestone payment from Roche following the approval.</p> <p>(This story corrects to remove reference to Japan approval from the third paragraph)</p> <p>(Reporting By Katharina Bart; Editing by Andrew Heavens and Louise Heavens)</p> <ul id="topics" class="hidden"> <li>Health</li> <li>Disease & Medical Conditions</li> <li>breast cancer</li> <li>ImmunoGen</li> </ul><p></p> //<!--[CDATA[ jQuery(".gmframe").load(function (){jQuery(this).remove();}); //]]--> <br><br>

Roche says Kadcyla wins European approval [ BeritaTerkini ]

ZURICH (Reuters) – Roche said on Wednesday its drug Kadcyla, a treatment for an aggressive form of breast cancer, ...

Read more »